Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.

Kristian B Filion Antonios Douros Laurent AzoulayHui YinOriana H YuSamy Suissa

Published in: British journal of clinical pharmacology (2019)

Initiating treatment of type 2 diabetes with a sulfonylurea rather than metformin is associated with higher rates of ischaemic stroke, cardiovascular death, and all-cause mortality.

Keyphrases

cardiovascular events
type diabetes
cardiovascular disease
coronary artery disease
insulin resistance
metabolic syndrome
combination therapy
skeletal muscle
adipose tissue